NeuBase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation (Tables)

Stock-Based Compensation (Tables)

3 Months Ended

Dec. 31, 2021

Schedule of stock-based compensation expense

The Company recorded stock-based compensation expense in the following expense categories of its unaudited condensed consolidated statements of operations for the three months ended December 31, 2021 and 2020:


	Three Months Ended December 31,
	2021		2020
General and administrative	$	327,131	$	842,279
Research and development		466,073		334,306
Total	$	793,204	$	1,176,585

Summary of stock options issued and outstanding

Below is a table summarizing the options issued and outstanding as of and for the three months ended December 31, 2021:


				Weighted
		Weighted		Average	Total
		Average		Remaining	Aggregate
		Exercise		Contractual Life	Intrinsic
	Stock Options	Price		(in years)	Value
Outstanding at September 30, 2021	7,397,154	$	3.13
Granted	105,000		3.59
Exercised	(42,250)		0.00
Forfeited	(262,500)		5.07
Outstanding at December 31, 2021	7,197,404		3.08	6.9	$	9,185,031
Exercisable as of December 31, 2021	5,360,067	$	2.33	6.2	$	9,184,698

Schedule of key assumptions used to estimate the fair value of the stock options granted

Key assumptions used to estimate the fair value of the stock options granted during the three months ended December 31, 2021 and 2020 included:


	Three Months Ended December 31,
	2021	2020
Expected term of options (years)	5.1 - 6.1	6.0
Expected common stock price volatility	73.8% - 74.5%	83.1% - 83.3%
Risk-free interest rate	1.1% - 1.4%	0.6% - 0.7%
Expected dividend yield	—	—

Summary of changes in the outstanding restricted stock

A summary of the changes in the unvested restricted stock during the three months ended December 31, 2021 is as follows:


			Weighted Average
			Grant Date
	Unvested Restricted		Fair Value
	Stock		Price
Unvested as of September 30, 2021		—	$	—
Granted		4,441		3.94
Vested		(4,441)		3.94
Unvested as of December 31, 2021		—		—
Total unrecognized expense remaining	$	—
Weighted-average years expected to be recognized over		—

Summary of restricted stock units granted and outstanding

Below is a table summarizing the restricted stock units granted and outstanding as of and for the three months ended December 31, 2021:


			Weighted Average
			Grant Date
	Restricted Stock		Fair Value
	Units		Price
Unvested as of September 30, 2021		10,000	$	5.09
Granted		—
Unvested as of December 31, 2021		10,000		5.09
Total unrecognized expense remaining	$	35,580
Weighted-average years expected to be recognized over		1.7